Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

– Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is

anticipated in 1Q25 –

– Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib that demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor –